AU2001267421A1 - Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders - Google Patents
Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disordersInfo
- Publication number
- AU2001267421A1 AU2001267421A1 AU2001267421A AU6742101A AU2001267421A1 AU 2001267421 A1 AU2001267421 A1 AU 2001267421A1 AU 2001267421 A AU2001267421 A AU 2001267421A AU 6742101 A AU6742101 A AU 6742101A AU 2001267421 A1 AU2001267421 A1 AU 2001267421A1
- Authority
- AU
- Australia
- Prior art keywords
- ht1a
- compounds
- cns disorders
- treating cns
- agonistic action
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 230000001270 agonistic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00201704 | 2000-05-12 | ||
| EP00201704 | 2000-05-12 | ||
| PCT/EP2001/005319 WO2001085168A1 (en) | 2000-05-12 | 2001-05-10 | Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001267421A1 true AU2001267421A1 (en) | 2001-11-20 |
Family
ID=8171490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001267421A Abandoned AU2001267421A1 (en) | 2000-05-12 | 2001-05-10 | Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030186838A1 (en) |
| EP (1) | EP1284731A1 (en) |
| JP (1) | JP2003532676A (en) |
| AU (1) | AU2001267421A1 (en) |
| CA (1) | CA2405758A1 (en) |
| WO (1) | WO2001085168A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ3370A1 (en) | 2000-05-12 | 2001-11-15 | Solvay Pharm Bv | PIPERAZINE AND PIPERIDINE COMPOUNDS |
| US7504395B2 (en) | 2001-07-20 | 2009-03-17 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
| AU2003244160A1 (en) * | 2002-06-25 | 2004-01-06 | Sumitomo Pharmaceuticals Co., Ltd. | Novel benzoxazolinone derivative |
| US7596407B2 (en) | 2004-03-26 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| EP1595542A1 (en) * | 2004-03-26 | 2005-11-16 | Solvay Pharmaceuticals B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| US9066903B2 (en) | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0185429A1 (en) * | 1984-12-21 | 1986-06-25 | Duphar International Research B.V | New bicyclic heteroaryl piperazines |
| DK203990D0 (en) * | 1990-08-24 | 1990-08-24 | Novo Nordisk As | piperazinyl |
| DK148392D0 (en) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocyclic Compounds |
| HU227454B1 (en) * | 1996-03-29 | 2011-06-28 | Duphar Int Res | Piperazine and piperidine compounds, process for their preparation and pharmaceutical compositions containing the same |
| EP0900792B1 (en) * | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
| FR2769912B1 (en) * | 1997-10-16 | 2000-03-10 | Pf Medicament | NEW 3-OXO- (2H) -1,2,4 TRIAZINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS |
| GB9811879D0 (en) * | 1998-06-03 | 1998-07-29 | Knoll Ag | Therapeutic agents |
| UA71590C2 (en) * | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
-
2001
- 2001-05-10 AU AU2001267421A patent/AU2001267421A1/en not_active Abandoned
- 2001-05-10 WO PCT/EP2001/005319 patent/WO2001085168A1/en not_active Application Discontinuation
- 2001-05-10 EP EP01945108A patent/EP1284731A1/en not_active Withdrawn
- 2001-05-10 CA CA002405758A patent/CA2405758A1/en not_active Abandoned
- 2001-05-10 US US10/275,813 patent/US20030186838A1/en not_active Abandoned
- 2001-05-10 JP JP2001581822A patent/JP2003532676A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001085168A1 (en) | 2001-11-15 |
| JP2003532676A (en) | 2003-11-05 |
| CA2405758A1 (en) | 2001-11-15 |
| US20030186838A1 (en) | 2003-10-02 |
| EP1284731A1 (en) | 2003-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001041701A3 (en) | The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist | |
| WO2001078702A3 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| AU9411701A (en) | Combination use of acetylcholinesterase inhibitors and gaba<sub>A</sub> inverse agonists for the treatment of cognitive disorders | |
| HUP0401192A3 (en) | Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds | |
| AU2001271567A1 (en) | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders | |
| WO2002038142A3 (en) | Serotonergic compositions and methods for treatment of mild cognitive impairment | |
| AU2003226014A1 (en) | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease | |
| AU2002363236A1 (en) | Compounds, pharmaceutical compositions and methods of use therefor | |
| WO2005013914A3 (en) | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain | |
| PL367264A1 (en) | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes | |
| AU2001264729A1 (en) | Thromboxane inhibitors, compositions and methods of use related applications | |
| AU3691301A (en) | Treatment of fluorocarbon feedstocks | |
| DE60122630D1 (en) | Titanium oxide, and photocatalyst and photocatalyst coating composition using the same | |
| CA2406057A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| AU2001249262A1 (en) | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof | |
| AU2001236868A1 (en) | Ophthalmic use of alpha adrenergic blocking agents | |
| AU2001267421A1 (en) | Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders | |
| EP1392280A4 (en) | Arylsulfonamide ethers, and methods of use thereof | |
| WO2002051848A3 (en) | Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors | |
| WO2002041894A3 (en) | Selective dopamine d4 receptor agonists for treating sexual dysfunction | |
| AU2874901A (en) | Treatment of fluorocarbon feedstocks | |
| AU3399401A (en) | Treatment of fluorocarbon feedstocks | |
| AU2002354698A1 (en) | Use of xaa-pro peptidases for the treatment of substance p-related disorders | |
| AU2000270300A1 (en) | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders | |
| EP1315499A4 (en) | Compositions and methods for the treatment of anorectal disorders |